Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine
Authors:
Open Access
- 1 April 2016
- journal article
- review article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 12, 585-597
Abstract
Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients’ quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug–drug interactions, and does not require dose adjustment in renal impairment. As bilastine is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the drug’s safety margin. Bilastine has demonstrated similar efficacy to cetirizine and desloratadine in patients with seasonal allergic rhinitis and, in a Vienna Chamber study, a potentially longer duration of action than fexofenadine in patients with asymptomatic seasonal allergic rhinitis. It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis. Bilastine showed similar efficacy to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses of up to fourfold higher than standard dosage (80 mg once daily). The fourfold higher than standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines. Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity. Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria.Keywords
This publication has 68 references indexed in Scilit:
- Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during drivingExpert Opinion on Drug Safety, 2015
- Development of a highly sensitive LC–MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2015
- Night‐time sedating H 1 ‐antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trialBritish Journal of Dermatology, 2014
- Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and UrticariaBioMed Research International, 2013
- Immunopathogenesis of allergic disorders: current conceptsExpert Review of Clinical Immunology, 2013
- Effects of Bilastine on T-wave Morphology and the QTc IntervalClinical Drug Investigation, 2012
- Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence reviewCurrent Medical Research and Opinion, 2011
- Pharmacology of AntihistaminesWorld Allergy Organization Journal, 2011
- Epidemiology of urticaria: a representative cross-sectional population surveyClinical and Experimental Dermatology, 2010
- Histamine H1receptor occupancy in human brains after single oral doses of histamine H1antagonists measured by positron emission tomographyBritish Journal of Pharmacology, 1995